Castrate-Sensitive Prostate Cancer Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight | Bristol-Myers Squibb, Myovant Sciences/Takeda, Merck Sharp & Dohme,

DelveInsight's 'Castrate-Sensitive Prostate Cancer Market Insights, Epidemiology and Market Forecast - 2034' report delivers an in-depth understanding of the CSPC, historical and forecasted epidemiology as well as the CSPC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Discover Key Insights into the Castrate-Sensitive Prostate Cancer Market with DelveInsight's In-Depth Report @ Castrate-Sensitive Prostate Cancer Market Size [https://www.delveinsight.com/sample-request/castrate-sensitive-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Castrate-Sensitive Prostate Cancer Market

* In March 2025, Janssen Research & Development, LLC initiated a study to evaluate whether intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC), who achieved a prostate-specific antigen (PSA) level of
* In March 2025, Aragon Pharmaceuticals Inc. launched a study to assess whether the addition of apalutamide to ADT offers superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) in participants with metastatic hormone-sensitive prostate cancer (mHSPC).
* The total cases of Castrate-Sensitive Prostate Cancer in the 7MM were found to be 763,077 in 2024 which is expected to grow during the study period, i.e., 2024-2034.
* The leading Castrate-Sensitive Prostate Cancer Companies such as Bristol-Myers Squibb, Myovant Sciences/Takeda, Merck Sharp & Dohme, Sophiris Bio, RhoVac, Advantagene and others
* Promising Castrate-Sensitive Prostate Cancer Therapies such as Apalutamide, GT0918, Saruparib, Abiraterone Acetate, Degarelix, Ipilimumab , and others.

Stay ahead in the Castrate-Sensitive Prostate Cancer Therapeutics Market with DelveInsight's Strategic Report @ Castrate-Sensitive Prostate Cancer Market Outlook [https://www.delveinsight.com/sample-request/castrate-sensitive-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Castrate-Sensitive Prostate Cancer Epidemiology Segmentation in the 7MM

* Total Prevalent Cases of Prostate Cancer
* Total Diagnosed Cases of Prostate Cancer
* Age-specific Cases of Prostate Cancer
* Total Diagnosed Cases of Prostate Cancer by Clinical Stages
* Total Non-metastatic and Metastatic Cases
* Total Treated Cases of Non-metastatic and Metastatic

Download the report to understand which factors are driving Castrate-Sensitive Prostate Cancer Epidemiology trends @ Castrate-Sensitive Prostate Cancer Prevalence [https://www.delveinsight.com/sample-request/castrate-sensitive-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Castrate-Sensitive Prostate Cancer Marketed Drugs

* Erleada (apalutamide): Janssen Pharmaceuticals

Erleada (apalutamide; Janssen Pharmaceutical) is a next-generation oral androgen receptor (AR) inhibitor that blocks the androgen signaling pathway in prostate cancer cells. It is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC/HSPC).

* Xtandi (Enzalutamide): Astellas Pharma/Pfizer

It is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. In December 2019, the US FDA granted approval to Xtandi (enzalutamide; Astellas Pharma) for use in the treatment of patients with metastatic CSPC. Prior to this, Xtandi was approved for castration-resistant prostate cancer. This approval was based on findings from the ARCHES clinical trial. The median rPFS rates in the Xtandi were not reached and for placebo arms was 19.4 months, respectively. In addition to this, in ARCHES trial statistically significant improvement in time to initiation of a new antineoplastic therapy with enzalutamide vs. placebo. The most common adverse reactions that occurred more frequently in enzalutamide-treated patients in ARCHES were hot flush, asthenia/fatigue, hypertension, fractures, and musculoskeletal pain.

Castrate-Sensitive Prostate Cancer Emerging Drugs

* Keytruda (pembrolizumab): Merck Sharp & Dohme

Keytruda, also known as pembrolizumab, is a PD-1 blocking antibody. It is product of Merck Sharp & Dohme. It is mainly used for cancers that are advanced, have spread to other parts of the body or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high levels of a protein known as PD-L1. It is approved for multiple types of cancer. This is currently being investigated in Phase III clinical trials in combination with Enzalutamide for the treatment of patients affected by mHSPC.

* Opdivo (nivolumab): Bristol-Myers Squibb

Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. This drug is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response. By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

* Relugolix: Myovant Sciences

Myovant Sciences also investigating their candidate Relugolix for Androgen-sensitive advanced prostate cancer. A phase III HERO study (NCT03085095; Recruiting) currently ongoing to determine the benefit and safety of Relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels ( less than or equal to 50 ng/dL [1.7 nmol/L] in participants with androgen-sensitive advanced prostate cancer. This is an international, randomized, open-label, parallel group efficacy and safety study.

* Topsalysin (PRX302): Sophiris Bio

Topsalysin (PRX302), an investigative agent of Sophiris Bio for localized prostate cancer. It is first-in-class transmembrane pore-forming protein, was genetically modified to be activated only by enzymatically-active PSA, which is produced in large quantities within the prostate of men with prostate cancer.

* ProstAtak: Advantagene

Advantagene is developing ProstAtak for the treatment of patients suffering from prostate cancer. ProstAtak jump-starts the body's own immune system to detect and destroy recurring cancer cells. The treatment is done together with standard radiation therapy. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- NCT02768363). However, enrollment is still open for prostate cancer patients choosing radiation therapy as their primary treatment (PrTK03- NCT01436968).

To learn more about Castrate-Sensitive Prostate Cancer treatment guidelines, visit @ Castrate-Sensitive Prostate Cancer Treatment Market Landscape [https://www.delveinsight.com/sample-request/castrate-sensitive-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Castrate-Sensitive Prostate Cancer Companies

Bristol-Myers Squibb, Myovant Sciences/Takeda, Merck Sharp & Dohme, Sophiris Bio, RhoVac, Advantagene and others.

Castrate-Sensitive Prostate Cancer Treatment Market

Prostate cancer is the second most common cancer in men can be categorized into castrate-sensitive (castration-sensitive prostate cancer [CSPC], and castration-resistant prostate cancer (mCRPC). This type of cancer only considered to be CSPC if it responds to medical or surgical treatment to lower a patient's testosterone levels. For the treatment of CSPC, Androgen-deprivation therapy (ADT) has been the cornerstone of therapy. However, most metastatic CSPC ( mCSPC/HSPC ) cannot be cured by ADT, and reemerges as metastatic castration-resistant prostate cancer (mCRPC). The treatment landscape of CSPC was not evolved until recent years.

Castrate-Sensitive Prostate Cancer Market Outlook

The report's outlook on the Castrate-Sensitive Prostate Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Castrate-Sensitive Prostate Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Castrate-Sensitive Prostate Cancer drug and late-stage pipeline therapy.

Learn more about the FDA-approved drugs for Castrate-Sensitive Prostate Cancer @ Drugs for Castrate-Sensitive Prostate Cancer Treatment [https://www.delveinsight.com/sample-request/castrate-sensitive-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Castrate-Sensitive Prostate Cancer Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Castrate-Sensitive Prostate Cancer Companies- Bristol-Myers Squibb, Myovant Sciences/Takeda, Merck Sharp & Dohme, Sophiris Bio, RhoVac, Advantagene and others
* Castrate-Sensitive Prostate Cancer Therapies- Apalutamide, GT0918, Saruparib, Abiraterone Acetate, Degarelix, Ipilimumab, and others.
* Castrate-Sensitive Prostate Cancer Market Dynamics: Castrate-Sensitive Prostate Cancer Market Drivers and Barriers
* Castrate-Sensitive Prostate Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Executive Summary of CSPC/HSPC

3. SWOT Analysis of CSPC/HSPC

4. CSPC/HSPC: Market Overview at a Glance

5. CSPC/HSPC: Disease Background and Overview

6. Diagnosis

7. Epidemiology and Patient Population

8. EU-5 Country-wise Epidemiology

9. Japan

10. Current Treatment Practices: Prostate Cancer

11. Guideline of Prostate Cancer

12. Unmet Needs of Prostate Cancer

13. Marketed Therapies

14. Emerging Therapies

15. CSPC/HSPC: Seven Major Market Analysis

16. 7MM Market Size

17. Market Access and Reimbursement of CSPC

18. Market Drivers of CSPC

19. Market Barriers of CSPC

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=castratesensitive-prostate-cancer-treatment-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight-bristolmyers-squibb-myovant-sciencestakeda-merck-sharp-dohme]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.